The EPS miss is notable but secondary to the barzolvolimab pipeline catalyst. The Phase 3 topline readout in Q4 2026 is the primary value driver. Traders should monitor for any safety signals or enrollment updates ahead of that date. The stock may trade on pipeline sentiment rather than quarterly financials in the near term.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $32.12entry
- T+1 · 5mo ago +0.62%α +1.22% · $32.32
- T+5 · 5mo ago +4.02%α +5.40% · $33.41
- T+20 · 4mo ago +19.96%α +20.71% · $38.53
- T+60 · 2mo ago +18.62%α +18.22% · $38.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long-term Phase 2 data for barzolvolimab in CSU, showing durable angioedema improvements off-treatment through Week 76. Phase 3 topline data is expected in Q4 2026, with a BLA submission planned for 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$1.18 missed consensus of -$1.07 (-10.8% miss)
- Revenue of $859K (consensus $859K), in line
- Phase 2 barzolvolimab data showed up to 64% of angioedema patients remained symptom-free 7 months after last dose
- Phase 3 CSU trials fully enrolled with 1,939 patients; topline data expected Q4 2026
- BLA submission planned for 2027
- No revenue guidance or financial outlook provided
Financial Impact
EPS miss of $0.11 per share vs consensus; no revenue surprise
Risk Factors
- Phase 3 barzolvolimab data may fail to replicate Phase 2 efficacy or show unexpected safety issues
- No approved products or recurring revenue; cash burn continues with no near-term commercialization
- Competition from existing CSU therapies (omalizumab, ligelizumab) could limit market opportunity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311449 |
Track record
21 reports on CLDX
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Viewing Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers